TMPRSS2 and neoplasm: Biomarkers between benign and malignant samples were analyzed using both NMR and LC-MS, with focuses on metabolic profiles that could identify the aggressiveness and progression of disease according to Gleason scores reflecting tumor aggressiveness and gene fusion, TMPRSS2-ERG, of progression.